New PET tracers aim to light up Hard-to-See cancers
NCT ID NCT07630961
First seen Jun 09, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This study tests two new radioactive imaging agents (JFI447 and FFG233) to see how well they show up on PET scans in people with advanced solid tumors like pancreatic, lung, breast, colorectal cancers, and sarcomas. The goal is to measure how the agents spread in the body and compare their ability to detect tumors. About 66 adults will participate to help improve cancer imaging.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGChuo Ku, Tokyo, 1040045, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.